Lee, Yeri
Kim, Donggeon
Chung, Philip E. D.
Lee, Minkyeong
Kim, Nahmju
Chang, Jihoon
Lee, Byoung Chul http://orcid.org/0009-0002-3990-2741
Article History
Received: 13 March 2024
Accepted: 30 May 2024
First Online: 21 June 2024
Declarations
:
: All authors are employed by KANAPH Therapeutics Inc.. Additionally, Yeri Lee, Donggeon Kim, Philip E.D. Chung, Minkyeong Lee, Nahmju Kim, Jihoon Chang, and Byoung Chul Lee have no conflicts of interest related to this research.
: Experimentica Ltd. (Finland): Efficacy study in CNV model was performed by Experimentica Ltd. All animals were treated in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, the EC Directive 2010/63/EU of the European Parliament and of the Council on the Protection of animals used for Scientific Purposes and using protocols approved and monitored by the Animal Experiment Board of Finland. Naason Science Inc. (Republic of Korea): Efficacy study in nonexudative AMD model was carried out according to KFDA guidelines for the care and use of laboratory animals and approved by IACUC. WuXi AppTec Co., Ltd. (Suzhou, China): Rabbit PK study was conducted at WuXi AppTec Co., Ltd., and in accordance with the WuXi IACUC standard animal procedures along with the IACUC guidelines that was in compliance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals.